Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.

Current cancer drug targets - 1 Sept 2006

Harada Hironori, Harada Yuka, Kimura Akiro

Abstract excerpt

Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells characterized by ineffective and inadequate hematopoiesis. MDS is also a susceptibility to acute myeloid leukemia (AML) and shown to be extremely resistant to current therapeutic strategies. MDS in a subset of 10-20% of patients arise after previous chemotherapy or radiation exposure for other malignancies. Because MDS is a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Core Binding Factor Alpha 2 Subunit
Share to RUNX1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Targeting

Share to Genetic Therapy

Share to Mutation

Share to Myelodysplastic Syndromes

Source

Identifiers

PMID: 17017876
DOI: 10.2174/156800906778194595

Genes

RUNX1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.PMID 17017876Read ↗

High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.Semantic proximity Read ↗

Pathophysiology of MDS: genomic aberrations.Semantic proximity Read ↗

The genetics of myelodysplastic syndromes and the opportunities for tailored treatmentsSemantic proximity Read ↗

Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.Semantic proximity Read ↗

Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemiaSemantic proximity Read ↗

Molecular Mechanisms Involved in the Progression of Myelodysplastic SyndromeSemantic proximity Read ↗

MDS: Recent progress in molecular pathogenesis and clinical aspects.Semantic proximity Read ↗

[Analysis of RUNX1 Gene Mutation in Patients with Myelodysplastic Syndrome].Semantic proximity Read ↗

The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia.Semantic proximity Read ↗

Unraveling the molecular pathophysiology of myelodysplastic syndromes.Semantic proximity Read ↗

Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.Semantic proximity Read ↗

Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.